| 18.09 0.44 (2.49%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.58 | 1-year : | 26.38 |
| Resists | First : | 19.34 | Second : | 22.58 |
| Pivot price | 17.31 |
|||
| Supports | First : | 16.62 |
Second : | 14.94 |
| MAs | MA(5) : | 17.66 |
MA(20) : | 17.43 |
| MA(100) : | 12.1 |
MA(250) : | 7.64 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.8  |
| %K %D | K(14,3) : | 45.4 |
D(3) : | 42.4 |
| RSI | RSI(14): 60.6 |
|||
| 52-week | High : | 19.34 | Low : | 3.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ADMA ] has closed below upper band by 17.8%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.44 - 18.51 | 18.51 - 18.59 |
| Low: | 17.66 - 17.73 | 17.73 - 17.82 |
| Close: | 17.95 - 18.07 | 18.07 - 18.21 |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Fri, 13 Sep 2024
Los Angeles Capital Management LLC Takes $903,000 Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Wed, 11 Sep 2024
ADMA Biologics, Inc. (NASDAQ:ADMA) Director Lawrence P. Guiheen Sells 9,000 Shares - MarketBeat
Wed, 11 Sep 2024
ADMA Biologics, Inc. (NASDAQ:ADMA) Position Lowered by Rice Hall James & Associates LLC - MarketBeat
Tue, 10 Sep 2024
Adma Biologics (ADMA) Recently Broke Out Above the 20-Day Moving Average - Yahoo Finance
Tue, 10 Sep 2024
ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Tue, 10 Sep 2024
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 233 (M) |
| Shares Float | 229 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 80 (%) |
| Shares Short | 9,020 (K) |
| Shares Short P.Month | 8,280 (K) |
| EPS | 0.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 10.5 % |
| Operating Margin | 36.5 % |
| Return on Assets (ttm) | 15 % |
| Return on Equity (ttm) | 20.7 % |
| Qtrly Rev. Growth | 78.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.41 |
| EBITDA (p.s.) | 0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 73 (M) |
| Levered Free Cash Flow | 44 (M) |
| PE Ratio | 129.21 |
| PEG Ratio | 0 |
| Price to Book value | 22.33 |
| Price to Sales | 12.76 |
| Price to Cash Flow | 57.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|